[go: up one dir, main page]

KR910000622A - 페닐 알카 (케)노 산 - Google Patents

페닐 알카 (케)노 산 Download PDF

Info

Publication number
KR910000622A
KR910000622A KR1019900007107A KR900007107A KR910000622A KR 910000622 A KR910000622 A KR 910000622A KR 1019900007107 A KR1019900007107 A KR 1019900007107A KR 900007107 A KR900007107 A KR 900007107A KR 910000622 A KR910000622 A KR 910000622A
Authority
KR
South Korea
Prior art keywords
oxy
propionic acid
enyl
methoxyphenyl
hex
Prior art date
Application number
KR1019900007107A
Other languages
English (en)
Other versions
KR0143404B1 (ko
Inventor
미토시 고노
다카히코 나카에
노부유끼 하마나카
Original Assignee
사노 가즈오
오노 야쿠힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노 가즈오, 오노 야쿠힝 고교 가부시키가이샤 filed Critical 사노 가즈오
Publication of KR910000622A publication Critical patent/KR910000622A/ko
Priority to KR97071140A priority Critical patent/KR0148213B1/ko
Application granted granted Critical
Publication of KR0143404B1 publication Critical patent/KR0143404B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/34—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/56—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to carbon atoms of six-membered aromatic rings and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/19—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/005—Analogues or derivatives having the five membered ring replaced by other rings
    • C07C405/0058—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a not condensed ring different from a five-membered ring
    • C07C405/0066—Analogues or derivatives having the five membered ring replaced by other rings having the side-chains or their analogues or derivatives attached to a not condensed ring different from a five-membered ring to a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/52—Unsaturated compounds containing hydroxy or O-metal groups a hydroxy or O-metal group being bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음

Description

페닐 알카(케)노 산
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 하기 일반식(Ⅰ)의 페닐 알카(케)노산 및 이의 비독성 염:
    상기식에서, A는 ⅰ)-NHCO-, ⅱ)-O-, ⅲ)-NHSO2-, ⅳ)-CO-, ⅴ)-CH2- 또는 ⅵ)-CH(OH)-이고: w는 ⅰ) C1-13 알킬렌, ⅱ)페닐렌 또는 ⅲ)이며: R1은 ⅰ)수소, ⅱ)C1-4 알킬, ⅲ)-COOH, ⅳ)포화 또는 불포화된, 헤테로원자로 하나의 질소를 함유하는 4 내지 7원 모노-사일클릭헤테로 환 또는, 포화 또는 불포화된, 옥소 그룹에 의해 치환된 헤테로원자로 하나의 질소을 함유하는 4 내지 7원 모노-사이클릭 헤테로 환, v)또는 ⅵ)-CH2OH이고: W 및 R1과 함께 A는
    두 개의 R2는 같거나 다른, ⅰ) 수소, ⅱ) C1-4 알킬 또는 ⅲ) 포화 또는 불포화된, 총 두 개 또는 세 개의 질소 및 황을 함유하는 4 내지 7원 모노-사이클릭 헤테로 환, 또는 부착된 질소와 함께 두 개의 R2는 포화 또는 불포화된 ⅰ) 헤테로원자로 하나의 질소를 함유하는 7내지 14원, 비-또는 트리-사이클릭 헤테로 환, 또는 ⅱ) 총 둘 또는 세 개의 질소 및 산소를 함유하는 4내지 7원, 모노-사이클릭 헤테로 환을 형성하고: Y는 에틸렌 또는 비닐렌이며, D는 ⅰ)-Z-B 또는 ⅱ)는 -R4 이며: Z는 C3-11 알킬렌 또는 알케닐렌이고:
    B는이며: 또는 B와 함께 Z은 C3-22 알킬이고: R3은 ⅰ) 수소, ⅱ) 할로겐, ⅲ) C1-8 알킬, 알콕시 또는 알킬티오 또는 ⅳ) C2-8알케닐, 알케닐옥시 또는 알케닐티오이며: n는 1내지 3이고: R4는 C1-7알킬렌이며: R5는 ⅰ) C1-12 알킬, ⅱ) C2-12 알케닐, ⅲ) C5-7 사이클로알킬 또는 ⅳ) 페네틸 또는, 환이 하나의 C1-4 알콕시에 의해 치환된 페네틸이고: 두 개의 R6는, 같거나 다른, ⅰ) C1-7 알킬, ⅱ) 벤질 또는 ⅲ) 페닐 또는 환이 하나의 C1-4 알킬에 의해 치환된 페닐이며: 및 두 개의 R7는, 같거나 다른, C1-4 알킬이고, 단 ⅰ) -A-W-R1가 벤젠 링 내의 3- 또는 4-탄소에 결합해야 하고, ⅱ) W이 페닐렌 또는인 경우, A는 -O-, -CO-, -CH2- 또는 CH(OH)-를 나타낼 수 없다.
  2. 제1항에 있어서, A가 -NHCO-인 화합물.
  3. 제2항에 있어서, 3-[1-6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(5-옥소-5-모르폴리노펜탄아미노)벤젠-2-일]프로피온산. 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산. 3-[1-[6-(4-N-프로폭시페닐)헥스-5E-에닐]옥]-4-(4--디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산. 3-[1-[6-(4-2-프로페닐)옥시페닐]헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산 3-[-[7-(4-메톡시페닐)-n-헵트-6E-에닐]옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산, 3-[1-[7-(4-메톡시페닐)-n-헵틸]옥시-4-(4-디메메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산. 3-[1-[6-(4-메톡시페닐)-n-헥실]옥시-4-(4-디메틸아미노카보닐부탄아미노)벤젠-2-일]프로피온산. 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-[4-(1-인돌리닐)카보닐부탄아미도]벤젠-2-일]프로피온산. 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-[4-2-티아졸일)아미노카보닐부탄아미도]벤젠-2-일]프로피온산. 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(3-디메틸아미노카보닐프로피온아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-메틸티오페닐)헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-메틸페닐)헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-클로로페닐)헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-카복실부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-카복실부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-카복실부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시 페닐)헥스-5E-에닐]옥시-4-아세트아미도벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-아세트아미도벤젠-2-일]프로피온산, 3-[1-[6-4-메톡시페닐)헥스-5E-에닐]옥시-4-(5-하이드록시메틸벤즈아미도)벤젠-2-일]프로피온산, 3-[1-[6-4-메톡시페닐)헥스-5E-에닐]옥시-4-4-하이드록시부탄아미도)벤젠-2-일]프로피온산, 3-[1-[6-4-메톡시페닐)헥스-5E-에닐]옥시-4-(3-하이드록시메틸벤즈아미도)벤젠-2-일]프로피온산. 3-[1-5E-7-하이드록시펜타데세닐)옥시-4-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산, 또는 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(4-디메틸아미노카보닐부탄아미도)벤젠-2-일]프로피온산인 화합물.
  4. 제1항에 있어서, A가 -O-인 화합물.
  5. 제4항에 있어서, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-카복실부톡시)벤젠-2-일]프로피온산, 3-[1-[5E-7-하이드록시-n-펜타데세닐]옥시-4-(4-카복실부틸)옥시벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시-n-펜타데세닐)옥시-4-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시펜타데세닐)옥시-3-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산, 3-[1-(5E,9E-7-하이드록시-n-펜타데세닐)옥시-4-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시-9-(4-메톡시페닐)노네닐]옥시-시-4-(4-카복실부틸)옥시벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시펜타데세닐)옥시-4-(3-카복실프로필)옥시벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시펜타데세닐)옥시-4-카복실메톡시벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(n-프로폭시벤젠-2-일]프로피온산, 3-[1-[6-(4-하이드록시)헥스-5E-에닐)옥시-3-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산, 3-[1-(5E-6-메틸-7-하이드록시-n-펜타데세닐)옥시-4-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(3-디메틸아미노카보닐-n-프로필)옥시벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(3-카복실프로필)옥시벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(4-카복실프로필)옥시벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(4-(2-피롤리돈-1일)-n-부톡시]벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥실]옥시-3-(4-디메틸아미노카보닐부틸)옥시벤젠-2-일]프로피온산 또는 3-[1-[6-(4-메톡시페닐)헥실]옥시-3-(4-카복실부틸)옥시벤젠-2-일]프로피온산인 화합물.
  6. 제1항에 있어서, A가 -NHSO2- 인 화합물.
  7. 제6항에 있어서, 3-[1-[6-(4-메톡시페닐)헥실]옥시-4-(4-메틸페닐)설포닐아미노벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥실]옥시-4-(3-디메틸-아미노카보닐-n-프로필)설포닐아미노벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-메틸페닐)설포닐아미노벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(3-디메틸아미노카보닐-n-프로필)설포닐아미노벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-메틸설포닐아미노벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-벤젠설포닐아미노벤젠-2-일]프로피온산, 또는 3-[1-[6-(4-에톡시페닐)헥스-5E-에닐]옥시-4-(3카보닐프로필)설포닐아미노벤젠-2-일]프로피온산인 화합물.
  8. 제1항에 있어서, A가 -CO- 인 화합물.
  9. 제8항에 있어서, 3-[1-6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-옥소-4-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산, 3-[1-6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(1-옥소-5-카복실펜틸)벤젠-2-일]프로피온산, 3-[1-6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(1-옥소-5-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산, 3-[1-6(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-옥소-4-카복실부틸)벤젠-2-일]프로피온산, 3-[1-6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-옥소-5-카복실펜틸)벤젠-2-일]프로피온산, 또는 3-[1-6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-옥소-5-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산인 화합물.
  10. 제1항에 있어서, A가 -CF2- 인 화합물.
  11. 제10항에 있어서, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-카복실부틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(4-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시-n-펜타데세닐)옥시-4-(4-디메틸아미노카보닐-n-부틸)벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시-n-펜타데세닐)옥시-4-(4-카복실부틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐)옥시-4-n-부틸벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐)옥시-3-(5-카복실펜틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐)옥시-3-(5-디메틸아미노카보닐펜틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐)옥시-4-(5-카복실펜틸)벤젠-2-일]프로피온산, 또는 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(5-디메틸아미노카보닐펜틸)벤젠-2-일]프로피온산인 화합물.
  12. 제1항에 있어서, A가 -CH(CH)- 인 화합물.
  13. 제12항에 있어서, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-하이드록시-4-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(1-하이드록시-5-카복시펜틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(1-하이드록시-5-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-하이드록시-4-카복실부틸)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-하이드록시-5-카복실펜틸)벤젠-2-일]프로피온산, 또는 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(1-하이드록시-5-디메틸아미노카보닐부틸)벤젠-2-일]프로피온산인 화합물.
  14. 제1항에 있어서, W 및 R1가 함께 A가
  15. 제14항에 있어서, 3-[1-[6-(4-메톡시페닐)헥실]옥시-4-(퍼하이드로-1,2-티아진-1,1,3-트리온-2-일)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(퍼하이드로-1,2-트리아진-1,1,3-트리온-2-일)벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(이소티아졸리딘-1,1,3-트리온-2-일)벤젠-2-일]프로피온산, 3-[-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-프탈이미도벤젠-2-일)프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-(N-아세틸-N-메실)아미노벤젠-2-일)프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-디메실아미노벤젠-2-일)프로피온산, 3-[1-(5E-7-하이드록시-n-펜타데세닐)옥시-4(퍼하이드로-1,2-티아진-1,1,3-트리온-2-일]벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-4-비스(n-부틸설포닐)아미노벤젠-2-일]프로피온산, 3-[1-(5E-7-하이드록시-n-펜타데세닐)옥시-4-디메실아미노벤젠-2-일]프로피온산, 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-디메실아미노벤젠-2-일)벤젠-2-일]프로피온산 또는 3-[1-[6-(4-메톡시페닐)헥스-5E-에닐]옥시-3-(퍼하이드로-1,2-티아진-1,1,3-트리온-2-일)벤젠-2-일]프로피온산인 화합물.
  16. (1)하기 일반식(Ⅱ) 또는 (Ⅸ)의 화합물을 산(포름산, 트리플루오로아세트산 등)으로 비누화시키거나, (2)하기 일반식 (Ⅲ), (Ⅳ), (Ⅴ), (Ⅵ), (Ⅶ), (Ⅷ), (Ⅸ), (Ⅹ), (XII), (XIII), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI) 또는 (XXII)의 화합물을 알칼리 (수산화 나트륨 등)를 사용하여 비누화시키거나, (3)하기 일반식(XIV)의 화합물을 환원시키거나, (4)경우에 따라 일반식(I)의 화합물을 상응하는 이의 염으로 전환시킴을 특징으로하여 일반식(I)의 화합물 및 이의 비독성 염을 제조하는 방법.
    상기식에서, A는 ⅰ) -NHCO-, ⅱ) -O-, ⅲ) -NHSO2-, ⅳ) -CO-, ⅴ) -CH2- 또는 ⅵ) -CH(OH)- 이고: W는 ⅰ) C1-13 알킬렌. ⅱ) 페닐렌 또는 ⅲ)이며:R1은 ⅰ)수소, ⅱ)C1-4 알킬, ⅲ) -COOH, ⅳ) 포화 또는 불포화된 레테로원자로서 하나의 질소를 함유하는 4내지 7원 모노-사이클릭 헤테로 환 또는, 포화 또는 불포화된, 옥소 그룹에 의해 치환된 헤테로원자로서 하나의 질소를 함유하는 4내지 7원 모노-사이클릭 헤테로 환, ⅴ)또는 ⅵ) -CH2OH이고: W 및 R1과 함께 A는
    두 개의 R2는 같거나 다른, ⅰ) 수소, ⅱ) C1-4 알킬 또는 ⅲ) 포화 또는 불포화된, 총 두 개 또는 세 개의 질소 및 황을 함유하는 4 내지 7원 모노-사이클릭 헤테로 환, 또는 부착된 질소와 함께 두개의 R2는 포화 또는 불포화된 ⅰ) 헤테로원자로서 하나의 질소를 함유사는 7 내지 14원, 비-또는 트리-사이클릭 헤테로 환, 또는 ⅱ) 전체둘 또는 세개의 질소 및 산소를 함유하는 4 내지 7원, 모노-사이클릭 헤테로 환을 형성하고: Y는 에틸렌 또는 비닐렌이며, D는 ⅰ) -Z-B 또는 ⅱ)이며: Z는 C3-11 알킬렌 또는 알케닐렌이고:
    B는이며: 또는 B와 함께 Z는 C3-22 알킬이고: R3은 ⅰ) 수소, ⅱ) 할로겐, ⅲ) C1-8 알킬, 알콕시 또는 알킬티오 또는 ⅳ) C2-8 알케닐, 알테닐옥시 또는 알케닐티오이며: n는 1내지 3이고: R4는 C1-7 알킬렌이며: R5는 ⅰ)C1-12 알킬, ⅱ) C2-12 알케닐, ⅲ) C5-7 사이클로알킬 또는 ⅳ) 페네틸 또는, 환이 하나의 C1-4 알콕시에 의해 치환된 페네틸이고; 두 개의 R6는, 같거나 다른, ⅰ) C1-7 알킬, ⅱ) 벤질 또는 ⅲ) 페닐 또는 환이 하나의 C1-4알킬에 의해 치환된 페닐이며; 두 개의 R7는, 같거나 다른, C1-4알킬이고, 단ⅰ) -A-W-R1가 벤젠 환 내의 3- 또는 4- 탄소에 결합해야 하고, ⅱ) W이 페닐렌 또는인 경우, A는 -O-, -CO-, -CH2- 또는 -CH(OH)-를 나타낼 수 없으며, A1은 ⅰ) -NHCO- 또는 ⅱ) -NHSO2- 이고; R″은 ⅰ) Rla의 그룹 (여기에서, Rla는 수소, 포화 또는 불포화된 헤테로원자로서 하나의 질소를 함유하는 4 내지 7원 모노-사이클릭 헤테로 환 또는, 옥소 또는 C1-4 알킬에 의해 비치환 또는 치환된, 헤테로원자로서 하나의 질소를 함유하는 4내지 7원 모노-사이클릭 헤테로호나이다.)
    ⅱ) -CO2H 또는 ⅲ)또는 W 및 R11과 함께 A1은
    ⅳ)또는 ⅴ) N-(SO2R6)2 는 에틸렌 또는 비닐렌이고: t-Bu는 t 부틸기이며: R16은 ⅰ) -CO2H 또는 ⅱ) 일반식이고 R12는 ⅰ) Rla그룹, ⅱ)ⅲ) -CO2CH3또는 ⅳ)이고: A″은 -NHSO2이며: R13은 ⅰ) -Rla그룹, ⅱ)ⅲ) -CH2OCHO 또는 ⅳ) -CO2H이고: W 및 R13과 함께 A″가
    ⅳ)또는 ⅴ) -N-(SO2R6)2이며: Et는 에틸이고:R14는 ⅰ) -Rla그룹, ⅱ)또는 ⅲ) -CO2Et 이며, A2는 ⅰ) -O- 또는 ⅱ) -CH2- 이고: R15는 ⅰ) 수소 또는 ⅱ) 아세틸 그룹이며: R17은 ⅰ)ii) -CH2OH 또는 ⅲ) -CO2H 이고: R18은 ⅰ) -CO2Et ⅱ)또는 ⅲ) -CH2OH 이고:R19는 ⅰ)또는 ⅱ) -CO2Et이다.
  17. 활성 성분으로서 제1항에서 청구된 일반식(I)의 페닐 알카(케)노 산, 또는 그의 약제학적으로 허용 가능한 산 부가염을 함유하는 약제학적 조성물.
  18. 류코트리엔 B4에 의해 유발된 다양한 질병의 예방 및/또는 치료에 사용하기 위한, 제1항에서 청구된 일반식 (I)의 페닐 알카(케)노 산 또는 그의 약제학적으로 허용 가능한 산부가염.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900007107A 1989-06-27 1990-05-18 페닐알칸(켄)산, 이의 제조방법 및 이를 포함하는 약제학적 조성물 KR0143404B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR97071140A KR0148213B1 (en) 1989-06-27 1997-12-12 Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP(?)?1-164213? 1989-06-27
JP16421389 1989-06-27
JP(?)?1-310545? 1989-12-01
JP31054589 1989-12-01
JP179990 1990-01-09
JP1-310545 1990-01-09
JP2-1799 1990-01-09
JP1-164213 1990-01-09
JP(?)?2-1799? 1990-01-09

Publications (2)

Publication Number Publication Date
KR910000622A true KR910000622A (ko) 1991-01-29
KR0143404B1 KR0143404B1 (ko) 1998-07-15

Family

ID=27275078

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1019900007107A KR0143404B1 (ko) 1989-06-27 1990-05-18 페닐알칸(켄)산, 이의 제조방법 및 이를 포함하는 약제학적 조성물
KR97071141A KR0148212B1 (en) 1989-06-27 1997-12-12 Phenylalkan (en)oic acids
KR97071140A KR0148213B1 (en) 1989-06-27 1997-12-12 Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR97071141A KR0148212B1 (en) 1989-06-27 1997-12-12 Phenylalkan (en)oic acids
KR97071140A KR0148213B1 (en) 1989-06-27 1997-12-12 Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same

Country Status (10)

Country Link
US (2) US5086065A (ko)
EP (3) EP0619296B1 (ko)
JP (2) JPH0739369B2 (ko)
KR (3) KR0143404B1 (ko)
AT (3) ATE150006T1 (ko)
CA (1) CA2019335C (ko)
DE (3) DE69030202T2 (ko)
DK (3) DK0619296T3 (ko)
ES (3) ES2083396T3 (ko)
GR (3) GR3018510T3 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273999A (en) * 1991-09-10 1993-12-28 Hoffmann-La Roche Inc. Carboxylic acid leukotriene B4 antagonists
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists
DE4224402A1 (de) * 1992-07-21 1994-01-27 Schering Ag Neue Pyridin-Derivate mit Leukotrien-B¶4¶-antagonistischer Wirkung
JP2983295B2 (ja) * 1994-10-13 1999-11-29 ファイザー・インコーポレーテッド ベンゾピランおよびベンゾ縮合した化合物、それらの製造方法ならびにロイコトリエンｂ▲下４▼（ｌｔｂ▲下４▼）アンタゴニストとしてのそれらの使用
WO1996011925A1 (en) * 1994-10-13 1996-04-25 Pfizer Inc. Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene b4' (ltb4) antagonists
US5559150A (en) * 1995-06-06 1996-09-24 3-Dimensional Pharmaceuticals, Inc. N,N-disulfonylated aminobenzene carboxlic acids and the use thereof as thrombin inhibitors
JP2001501202A (ja) 1996-09-26 2001-01-30 ノバルティス アクチエンゲゼルシャフト ロイコトリエンｂ４（ｌｔｂ―４）レセプターアンタゴニスト活性によるアリル置換アクリルアミド
EP0891772A3 (en) * 1997-06-18 1999-05-19 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising nonsteroidal anti-inflamatory drug and phenylpropionic acid derivative
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
BRPI0413968A (pt) 2003-09-01 2006-10-31 Ono Pharmaceutical Co composto de anel condensado e seu uso
EP1670445A2 (en) * 2003-09-17 2006-06-21 Decode Genetics EHF. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
PT1988085E (pt) * 2006-02-21 2015-02-05 Toyama Chemical Co Ltd Processo para a produção de éster de propionato de 3-[5-[4-(ciclopentiloxi)-2-hidroxibenzoil]-2-[(3- hidroxi-1,2-benzisoxazol-6-il)metoxi]fenilo] e produtos intermédios para o processo
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
RU2560147C2 (ru) 2010-06-21 2015-08-20 Оно Фармасьютикал Ко., Лтд. Новые кристаллические формы 4, 4'- [4-фтор-7({4-[4-(3-фтор-2-метилфенил)бутокси]фенил}этинил)-2-метил-1н-индол-1, 3-диил]дибутановой кислоты, 4, 4'-[2-метил-7-({4-[4-(пентафторфенил)бутокси] фенил}этинил)-1н-индол-1, 3-диил]дибутановой кислоты и 4, 4'-[4-фтор-2-метил-7-({4-[4-(2, 3, 4, 6-тетрафторфенил) бутокси]фенил}этинил)-1н-индол-1, 3-диил]дибутановой кислоты
EP3268085A4 (en) 2015-03-13 2018-10-31 The Board of Trustees of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
CA1315279C (en) * 1987-01-12 1993-03-30 Nancy Grace Bollinger Anti-inflammatory agents
CA1320490C (en) * 1987-01-12 1993-07-20 Darrel M. Gapinski Anti-inflammatory agents

Also Published As

Publication number Publication date
GR3018510T3 (en) 1996-03-31
EP0619296A1 (en) 1994-10-12
ES2102097T3 (es) 1997-07-16
DK0652208T3 (da) 1998-09-14
DE69030202D1 (de) 1997-04-17
JPH0672947A (ja) 1994-03-15
EP0652208A1 (en) 1995-05-10
ES2083396T3 (es) 1996-04-16
EP0405116A3 (en) 1992-04-15
EP0619296B1 (en) 1997-03-12
ATE162181T1 (de) 1998-01-15
CA2019335C (en) 2000-08-01
EP0405116A2 (en) 1991-01-02
EP0652208B1 (en) 1998-01-14
DK0619296T3 (da) 1997-05-05
KR0148213B1 (en) 1998-08-17
DE69030202T2 (de) 1997-07-10
ATE150006T1 (de) 1997-03-15
JPH0819040B2 (ja) 1996-02-28
GR3022801T3 (en) 1997-06-30
KR0143404B1 (ko) 1998-07-15
DE69031959D1 (de) 1998-02-19
DE69023960D1 (de) 1996-01-18
US5086065A (en) 1992-02-04
DE69031959T2 (de) 1998-06-04
CA2019335A1 (en) 1990-12-27
GR3026351T3 (en) 1998-06-30
JPH03261752A (ja) 1991-11-21
ES2114117T3 (es) 1998-05-16
EP0405116B1 (en) 1995-12-06
ATE131154T1 (de) 1995-12-15
DE69023960T2 (de) 1996-10-17
US5155104A (en) 1992-10-13
DK0405116T5 (da) 1996-04-29
KR0148212B1 (en) 1998-08-17
JPH0739369B2 (ja) 1995-05-01

Similar Documents

Publication Publication Date Title
KR910000622A (ko) 페닐 알카 (케)노 산
KR890012954A (ko) 스틸벤 유도체
ATE1283T1 (de) Neue prostanderivate, ihre herstellung und sie enthaltende arzneimittel.
SE7711168L (sv) Nya 1-aryloxi-2-hydroxi-3-alkylenaminopropaner och forfarande for deras framstellning
SE7714592L (sv) Cyklopentan-1-aminer, forfarande for framstellning derav och medel innehallande dessa foreningar
WO1988000042A1 (en) New 5-alkoxy-2,4-diamino-alkyl benzols, and hair tinting means using them
KR930703236A (ko) 리그난 유사체. 이의 제조방법 및 이를 함유한 항지혈증제
SE7906472L (sv) Nya 3-(aminoetyl)-fenol-derivat och salter derav, sett for framstellning och anvendning derav sasom lekemedel samt farmaceutiska kompositioner innehallande dessa foreningar
ES543421A0 (es) Un procedimiento para preparar 1,3,4,5-tetrahidro-benz(cd) indolaminas oxigenadas en posicion 6
FI831388L (fi) 2-/2'-hydroxi-3'-(1,1-dimetylpropylamino)-propoxi/- -fenylpropionfenon, syreadditionssalter av denna foerfarande foer framstaellning av denna och farmaceutiska sammansaettningar
ATE16701T1 (de) Neue indanyl-derivate, ihre herstellung und verwendung.
FI910346A0 (fi) Nya leukotrien b4-derivat, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
ATE107639T1 (de) Neue alkanophenone.
NO160445C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
KR900003118A (ko) 술폰아미도시클로알칸화합물, 이것의 제조방법 및 이것을 함유하는 제약조성물
FI923440A (fi) 6-oxo-azepinoindolfoereningar samt foerfaranden och mellanprodukter foer deras framstaellning
JPS5562064A (en) Isatin derivative
ES2135711T4 (es) Derivados de tiazolidindiona como agentes antihiperglucemicos.
SE8302345L (sv) Pleuromutilinderivat, forfaranden for deras framstellning och deras anvendning som lekemedel
KR900009633A (ko) N-치환 아실아미노산 화합물, 이의 제조방법 및 이의 용도
SE7506803L (sv) Hexahydro-diazepino-indolderivat och forfarande for framstellning derav
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.
SE8405430D0 (sv) 7-acylindolforeningar, lempade som mellanprodukter vid synteser av 7-acylindolin-2-oner
ATE120188T1 (de) 15-deoxyprostaglandinderivat.
ES2076247T3 (es) Derivados de la pteridina farmaceuticamente eficaces.

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900518

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19930720

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900518

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970227

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970812

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19980217

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980408

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980408

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010328

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020403

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20030328

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20030328

Start annual number: 6

End annual number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20050111